Inhibikase Therapeutics, Inc.
IKT
$2.41
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -23.43M | 7.65M | -- |
| Gross Profit | -- | -- | 23.43M | -7.65M | -- |
| SG&A Expenses | 7.66M | 7.38M | 6.77M | 5.61M | 5.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.05M | 18.22M | 5.73M | 13.26M | 10.49M |
| Operating Income | -21.05M | -18.22M | -5.73M | -13.26M | -10.49M |
| Income Before Tax | -19.59M | -16.38M | -12.73M | -11.93M | -9.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.59M | -16.38M | -12.73M | -11.93M | -9.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.59M | -16.38M | -12.73M | -11.93M | -9.92M |
| EBIT | -21.05M | -18.22M | -5.73M | -13.26M | -10.49M |
| EBITDA | -21.04M | -18.20M | -5.73M | -13.24M | -10.47M |
| EPS Basic | -0.11 | -0.10 | -0.10 | -0.13 | -0.11 |
| Normalized Basic EPS | -0.07 | -0.06 | -0.02 | -0.09 | -0.07 |
| EPS Diluted | -0.11 | -0.10 | -0.10 | -0.13 | -0.11 |
| Normalized Diluted EPS | -0.07 | -0.06 | -0.02 | -0.09 | -0.07 |
| Average Basic Shares Outstanding | 174.57M | 172.31M | 123.64M | 90.05M | 90.01M |
| Average Diluted Shares Outstanding | 174.57M | 172.31M | 123.64M | 90.05M | 90.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |